Weight loss for a healthy liver

Gastroenterology

Volumn 149, Issue 2, 2015, Pages 274-278

  Marchesini, Giulio ^a   Mazzella, Natalia ^a   Forlani, Gabriele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARAMCHOL; BILE ACID CONJUGATE; CENICRIVIROC; ELAFIBRANOR; LIRAGLUTIDE; MONOCLONAL ANTIBODY; OBETICHOLIC ACID; SINTUZUMAB; UNCLASSIFIED DRUG;

BARIATRIC SURGERY; BEHAVIOR THERAPY; COGNITIVE THERAPY; COMORBIDITY; DISEASE COURSE; FOLLOW UP; HUMAN; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPID LIVER LEVEL; LIPID STORAGE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MOTIVATION; NONALCOHOLIC FATTY LIVER; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; TREATMENT FAILURE; WEIGHT CONTROL; WEIGHT REDUCTION; BODY MASS; FEMALE; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PATHOLOGY; PROCEDURES;

BARIATRIC SURGERY; BODY MASS INDEX; FEMALE; HUMANS; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; WEIGHT LOSS;

EID: 84938077197     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.06.015     Document Type: Editorial

References (20)

1. N. Chalasani, Z. Younossi, J.E. Lavine, and et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 2012 1592 1609
2. K. Promrat, D.E. Kleiner, H.M. Niemeier, and et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis Hepatology 51 2010 121 129
3. The Diabetes Prevention Program Research Group The Diabetes Prevention Program (DPP): description of lifestyle intervention Diabetes Care 25 2002 2165 2171
4. R. Caiazzo, G. Lassailly, E. Leteurtre, and et al. Roux-en-Y gastric bypass versus adjustable gastric banding to reduce nonalcoholic fatty liver disease: a 5-year controlled longitudinal study Ann Surg 260 2014 893 898 discussion 898-899
5. E. Vilar-Gomez, Y. Martinez-Perez, L. Calzadilla-Bertot, and et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis Gastroenterology 149 2015 367 378
6. G. Lassailly, R. Caiazzo, D. Buob, and et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients Gastroenterology 149 2015 379 388
7. J. Graham Thomas, D.S. Bond, S. Phelan, and et al. Weight-loss maintenance for 10 years in the National Weight Control Registry Am J Prev Med 46 2014 17 23
8. S. Bellentani, R. Dalle Grave, A. Suppini, and et al. Behavior therapy in nonalcoholic fatty liver disease: The need for a multidisciplinary approach Hepatology 47 2008 746 754
9. P. Mathurin, A. Hollebecque, L. Arnalsteen, and et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease Gastroenterology 137 2009 532 540
10. T.A. Wadden, M.L. Butryn, and C. Wilson Lifestyle modification for the management of obesity Gastroenterology 132 2007 2226 2238
11. N. Puzziferri, T.B. Roshek 3rd, H.G. Mayo, and et al. Long-term follow-up after bariatric surgery: a systematic review JAMA 312 2014 934 942
12. V. Ratziu, Z. Goodman, and A. Sanyal Current efforts and trends in the treatment of NASH J Hepatol 62 2015 S65 S75
13. T.A. Wadden, R.I. Berkowitz, L.G. Womble, and et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity N Engl J Med 353 2005 2111 2120
14. B.A. Neuschwander-Tetri, R. Loomba, A.J. Sanyal, and et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 385 2015 956 965
15. M.J. Armstrong, P. Gaunt, G.P. Aithal, and et al. Liraglutide is effective in the histological clearance of non-alcoholic steatohepatitis in a multicentre, double-blinded, randomised, placebo-controlled phase II trial J Hepatol 62 2015 S-187
16. B. Cariou, R. Hanf, S. Lambert-Porcheron, and et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects Diabetes Care 36 2013 2923 2930
17. GENFIT. GENFIT announces topline results from the GOLDEN-505 trial in NASH. Available from: www.genfit.com/wp-content/uploads/2015/03/2015.03.26-PR-GENFIT-Golden505-results.pdf. Accessed June 5, 2015.
18. A.L. Fracanzani, L. Valenti, E. Bugianesi, and et al. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity J Hepatol 54 2011 1244 1249
19. A.B. Goldfine Assessing the cardiovascular safety of diabetes therapies N Engl J Med 359 2008 1092 1095
20. M. Ekstedt, H. Hagstrom, P. Nasr, and et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up Hepatology 61 2015 1547 1554